Skip to main content
[Preprint]. 2024 Jul 5:2024.07.02.24309792. [Version 1] doi: 10.1101/2024.07.02.24309792

Figure 3. Decreased bispecific antibody-dependent killing by CD4+ T-cell subsets.

Figure 3.

(a) Schematic for epcoritamab-dependent B-cell killing assay. (b) Fractional killing of RAJI B-cells by epcoritamab in the setting of co-culture with distinct T-cell subsets, measured by luciferase activity relative to culture with no T-cells.